The approval represents a significant moment in the treatment of structural heart disease. Edwards will share updated data on the device at TCT 2023 in San Francisco.  

Interventional cardiologist Alfred G. Valles, MD, was 50 years old at the time of the accident. According to colleagues, he "strived daily to achieve his vision for world-class care."

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects. 

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

Researchers hopes this first-in-class gene therapy, known as TN-201, can restore the patient’s MYBPC3 levels and eventually lead to disease reversal.

The self-expanding valve, already approved by the FDA, was designed with three gold markers to boost implanter efficiency, an updated catheter tip and a more flexible delivery system.

ACC President Hadley Wilson, MD, explains the big impact four late-breaking studies on intravascular imaging may have on revising PCI guidelines.

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.